Related Experiment Videos

Oral antipyretic therapy. Evaluation of mefenamic acid (short communication)

Arzneimittel-Forschung
|January 1, 1977
PubMed

Insights

Mefenamic acid (N-(2,3-xylyl)anthranilic acid) effectively reduces fever in children. Its antipyretic capacity is significantly higher than acetylsalicylic acid or paracetamol, and comparable to aminophenazone.

Area of Science:

  • Pediatrics
  • Pharmacology
  • Clinical Medicine

Background:

  • Fever management in children is crucial.
  • Comparison of antipyretic drugs is essential for clinical practice.
  • N-(2,3-xylyl)anthranilic acid (mefenamic acid) is a potential antipyretic agent.

Purpose of the Study:

  • To compare the antipyretic efficacy of mefenamic acid with acetylsalicylic acid, paracetamol, and aminophenazone in children.
  • To evaluate the dose-response relationship of mefenamic acid as an antipyretic.
  • To assess the onset and duration of antipyretic action of mefenamic acid.

Main Methods:

  • A comparative study involving 71 pediatric patients (3 months to 15 years) with rectal temperatures above 38.5°C.
  • Administration of mefenamic acid (4 mg/kg), acetylsalicylic acid, paracetamol, and aminophenazone.
  • Rectal temperature measurements at 15, 30 minutes, and 1, 2, 4, and 6 hours post-administration.

Main Results:

  • Mefenamic acid (4 mg/kg) demonstrated optimal antipyretic effect.
  • The antipyretic efficacy of mefenamic acid was 2.5 times greater than that of acetylsalicylic acid or paracetamol.
  • Mefenamic acid's antipyretic effect was nearly similar to that of aminophenazone.

Conclusions:

  • Mefenamic acid exhibits a potent antipyretic effect in children.
  • The antipyretic properties of mefenamic acid may exceed its anti-inflammatory and analgesic effects.
  • Mefenamic acid is a promising option for fever reduction in pediatric populations.

Related Concept Videos